Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solesence (SLSN) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Solesence (SLSN) over the last 14 years, with Sep 2025 value amounting to $252,000.

  • Solesence's Other Non-Current Liabilities rose 3.28% to $252,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $252,000, marking a year-over-year increase of 3.28%. This contributed to the annual value of $246,000 for FY2024, which is 3.36% up from last year.
  • According to the latest figures from Q3 2025, Solesence's Other Non-Current Liabilities is $252,000, which was up 0.80% from $250,000 recorded in Q2 2025.
  • Over the past 5 years, Solesence's Other Non-Current Liabilities peaked at $252,000 during Q3 2025, and registered a low of $216,000 during Q1 2021.
  • Its 3-year average for Other Non-Current Liabilities is $242,000, with a median of $242,000 in 2024.
  • Data for Solesence's Other Non-Current Liabilities shows a peak YoY climbed of 4.13% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Solesence's Other Non-Current Liabilities stood at $222,000 in 2021, then increased by 3.60% to $230,000 in 2022, then rose by 3.48% to $238,000 in 2023, then rose by 3.36% to $246,000 in 2024, then grew by 3.28% to $252,000 in 2025.
  • Its Other Non-Current Liabilities stands at $252,000 for Q3 2025, versus $250,000 for Q2 2025 and $248,000 for Q1 2025.